SAP announces planned merger with subsidiary LeanIX

Christian Klein Chief Executive Officer (CEO) SAP SE
Christian Klein Chief Executive Officer (CEO) - SAP SE
0Comments

SAP SE has announced plans to merge LeanIX GmbH into its operations. LeanIX GmbH, registered in the local court of Bonn under HRB 19137, will transfer all its assets, rights, and obligations to SAP SE effective January 1, 2025. From this date until the formal dissolution of LeanIX GmbH as per Sec. 20 para. 1 No.2 UmwG, any actions taken by LeanIX GmbH will be considered on behalf of SAP SE.

SAP SE is the sole owner of LeanIX GmbH, which negates the need for a merger resolution from SAP SE’s board according to Sec. 62 para. 1 sent. 1 UmwG. Additionally, since SAP holds all shares in LeanIX GmbH, there is no requirement for a merger report or audit as stipulated by Secs. 8 para. 3 sent. 3 no. 1 a), 9 para. 2, and other relevant sections.

Shareholders holding at least one-twentieth of SAP SE’s share capital are informed that they have the right to request a general meeting to discuss approval of the merger under Sec. 62 para. 2 sent. 1 and subsequent sections.

The necessity for a shareholder meeting resolution from LeanIX GmbH regarding the merger agreement is waived due to SAP being its sole shareholder per section 62 para.4 sent.1 UmwG.

Documents related to this merger are available through specified links and include draft agreements and financial statements for both companies involved over recent fiscal years:

– SAP SE Statutory Financial Statements and Review of Operations (2022-2024)
– LeanIX GmbH Financial Statements (2021-2023)

SAP SE issued this information on May 23, 2025.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.